Literature DB >> 29427012

[Blood pressure targets : The lower the better does not suit all].

U Hoffmann1.   

Abstract

BACKGROUND: The systolic blood pressure intervention trial (SPRINT) published in 2015 has opened up new discussions on whether a lower blood pressure target as recommended by the current guidelines would be better for some patient groups.
OBJECTIVES: To review patient groups in which lower blood pressure targets would not be better.
MATERIALS AND METHODS: The results of SPRINT, its post-hoc and subgroup analyses, other studies and newer studies, as well as metaanalyses on the topic of blood pressure targets are reviewed and discussed. Studies with patients excluded from the SPRINT study were also analysed. The current international guidelines and recommendations of the Deutsche Hochdruckliga e. V. DHL® are included.
RESULTS: Blood pressure monitoring methods differed considerably in the previously published studies. The low blood pressure value in SPRINT was mainly achieved due to the unusual method of blood pressure monitoring used and, as such, cannot be compared with blood pressure values in other studies. Based on current evidence, "the lower the better" should not be recommended in the following patient groups: older patients, in particular infirm older patients, patients with diabetes, patients without coronary heart disease or with low cardiovascular risk.
CONCLUSIONS: When determining a blood pressure target, the method of blood pressure monitoring should be defined. A lower blood pressure target has been shown to be better in some well defined patient groups. However, adverse events due to antihypertensive medications should always be taken into account. Given the multiple exclusion criteria in trials and the results of many studies, "new" lower blood pressure targets could not be recommended in a large population of patients.

Entities:  

Keywords:  Adverse drug reactions; Antihypertensive agents; Blood pressure determination; Hypertension, arterial; Infirm elderly persons

Mesh:

Substances:

Year:  2018        PMID: 29427012     DOI: 10.1007/s00108-018-0388-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

Review 1.  Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients.

Authors:  Chirag Bavishi; Sripal Bangalore; Franz H Messerli
Journal:  J Am Coll Cardiol       Date:  2017-02-07       Impact factor: 24.094

2.  Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial.

Authors:  Nigel Beckett; Ruth Peters; Gastone Leonetti; Joe Duggan; Robert Fagard; Lut Thijs; Krzysztof Narkiewicz; Terry McCormack; Winston Banya; Astrid Fletcher; Christopher Bulpitt
Journal:  J Hypertens       Date:  2014-07       Impact factor: 4.844

3.  2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.

Authors:  Sripal Bangalore; Yan Gong; Rhonda M Cooper-DeHoff; Carl J Pepine; Franz H Messerli
Journal:  J Am Coll Cardiol       Date:  2014-08-26       Impact factor: 24.094

Review 4.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

5.  Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study.

Authors:  Paul E Drawz; Nicholas M Pajewski; Jeffrey T Bates; Natalie A Bello; William C Cushman; Jamie P Dwyer; Lawrence J Fine; David C Goff; William E Haley; Marie Krousel-Wood; Andrew McWilliams; Dena E Rifkin; Yelena Slinin; Addison Taylor; Raymond Townsend; Barry Wall; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2016-11-14       Impact factor: 10.190

Review 6.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

7.  Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial.

Authors:  Michelle C Odden; Carmen A Peralta; Dan R Berlowitz; Karen C Johnson; Jeffrey Whittle; Dalane W Kitzman; Srinivasan Beddhu; John W Nord; Vasilios Papademetriou; Jeff D Williamson; Nicholas M Pajewski
Journal:  JAMA Intern Med       Date:  2017-04-01       Impact factor: 21.873

Review 8.  Should blood pressure goal be individualized in hypertensive patients?

Authors:  Alexandra Yannoutsos; Rania Kheder-Elfekih; Jean-Michel Halimi; Michel E Safar; Jacques Blacher
Journal:  Pharmacol Res       Date:  2016-12-02       Impact factor: 7.658

9.  Generalizability of SPRINT Results to the U.S. Adult Population.

Authors:  Adam P Bress; Rikki M Tanner; Rachel Hess; Lisandro D Colantonio; Daichi Shimbo; Paul Muntner
Journal:  J Am Coll Cardiol       Date:  2015-11-09       Impact factor: 24.094

Review 10.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.